AU2003267700A1 - Rational directed protein evolution using two-dimensional rational mutagenesis scanning - Google Patents

Rational directed protein evolution using two-dimensional rational mutagenesis scanning

Info

Publication number
AU2003267700A1
AU2003267700A1 AU2003267700A AU2003267700A AU2003267700A1 AU 2003267700 A1 AU2003267700 A1 AU 2003267700A1 AU 2003267700 A AU2003267700 A AU 2003267700A AU 2003267700 A AU2003267700 A AU 2003267700A AU 2003267700 A1 AU2003267700 A1 AU 2003267700A1
Authority
AU
Australia
Prior art keywords
rational
dimensional
protein evolution
directed protein
mutagenesis scanning
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003267700A
Inventor
Hugo Cruz Ramos
Lila Drittanti
Rene Gantier
Thierry Guyon
Manuel Vega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nautilus Biotech SA
Original Assignee
Nautilus Biotech SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nautilus Biotech SA filed Critical Nautilus Biotech SA
Publication of AU2003267700A1 publication Critical patent/AU2003267700A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1089—Design, preparation, screening or analysis of libraries using computer algorithms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
AU2003267700A 2002-09-09 2003-09-08 Rational directed protein evolution using two-dimensional rational mutagenesis scanning Abandoned AU2003267700A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41025802P 2002-09-09 2002-09-09
US60/410,258 2002-09-09
US45706303P 2003-03-21 2003-03-21
US60/457,063 2003-03-21
PCT/IB2003/004255 WO2004022747A1 (en) 2002-09-09 2003-09-08 Rational directed protein evolution using two-dimensional rational mutagenesis scanning

Publications (1)

Publication Number Publication Date
AU2003267700A1 true AU2003267700A1 (en) 2004-03-29

Family

ID=31981644

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003267700A Abandoned AU2003267700A1 (en) 2002-09-09 2003-09-08 Rational directed protein evolution using two-dimensional rational mutagenesis scanning

Country Status (4)

Country Link
EP (1) EP1539950A1 (en)
AU (1) AU2003267700A1 (en)
CA (1) CA2498284A1 (en)
WO (1) WO2004022747A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7647184B2 (en) 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
US7611700B2 (en) 2002-09-09 2009-11-03 Hanall Pharmaceuticals, Co., Ltd. Protease resistant modified interferon alpha polypeptides
WO2006076014A2 (en) * 2004-04-30 2006-07-20 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Interferon-alpha constructs for use in the treatment of sars
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2006024547A2 (en) * 2004-09-03 2006-03-09 Creabilis Therapeutics S.P.A. Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
EP2476428B1 (en) 2005-06-29 2013-08-21 Yeda Research and Development Co. Ltd. Recombinant interferon alpha 2 (IFN alpha 2) mutants
WO2007110231A2 (en) * 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
EP2084274A2 (en) 2006-06-19 2009-08-05 Nautilus Technology LLC Modified coagulation factor ix polypeptides and use thereof for treatment
KR100944034B1 (en) 2007-04-19 2010-02-24 한올제약주식회사 Oral dosage formulations of protease-resistant polypeptides
ATE548381T1 (en) 2008-05-29 2012-03-15 Hanall Biopharma Co Ltd MODIFIED ERYTHROPOIETIN (EPO) POLYPEPTIDES WITH INCREASED PROTEASE RESISTANCE AND PHARMACEUTICAL COMPOSITIONS THEREOF
JP5746191B2 (en) * 2009-10-19 2015-07-08 ハナル バイオファーマ カンパニーリミテッドＨａｎＡｌｌ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof and method for producing the same
JP6184965B2 (en) 2011-10-28 2017-08-23 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド Polypeptide constructs and uses thereof
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
UA119352C2 (en) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof
EP3212216A4 (en) 2014-10-29 2018-04-18 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha2b variants
JP2022504822A (en) 2018-10-11 2022-01-13 インヒブルクス インコーポレイテッド DLL3 single domain antibody and therapeutic composition thereof
WO2020077257A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
CN113166261A (en) 2018-10-11 2021-07-23 印希比股份有限公司 B7H3 single domain antibodies and therapeutic compositions thereof
WO2020076992A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. 5t4 single domain antibodies and therapeutic compositions thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO2001061344A1 (en) * 2000-02-17 2001-08-23 California Institute Of Technology Computationally targeted evolutionary design
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis

Also Published As

Publication number Publication date
EP1539950A1 (en) 2005-06-15
CA2498284A1 (en) 2004-03-18
WO2004022747A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
AU2003267700A1 (en) Rational directed protein evolution using two-dimensional rational mutagenesis scanning
AU2003296374A1 (en) Software analysis framework
AU2003225278A1 (en) Secure scan
AU2003206048A1 (en) Bread comprising soy protein
AU2003297059A1 (en) Chip-in-a-well scanning
EP1595127A3 (en) Chip-in-a-well scanning
GB0201808D0 (en) Protein
GB0208089D0 (en) Protein
AU2003278718A8 (en) Stars-a muscle-specification-binding protein
AU2003254865A1 (en) Akt2-BINDING PROTEIN
GB0202748D0 (en) Protein
GB0215227D0 (en) Protein
GB0204735D0 (en) Protein
AU2003906501A0 (en) Protein evolution
GB0214872D0 (en) Poor visbility scanner
AU2003218714A1 (en) Rhomboid-related protein
GB0205266D0 (en) Protein
GB0208278D0 (en) Protein
GB0212532D0 (en) Protein
GB0211830D0 (en) Protein
GB0206867D0 (en) Protein
GB0205811D0 (en) Protein
GB0211671D0 (en) Protein
GB0205268D0 (en) Protein
GB0209488D0 (en) Protein

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase